Recro Pharma, Inc. (37)

Browse by Contract Category

Contracts

Sixth Amendment to Credit Agreement, dated as of August 13, 2021, by and among Recro Pharma, Inc., certain subsidiaries of Recro Pharma, Inc., named as guarantors therein, the... (Filed With SEC on August 13, 2021)
Form of Award Agreement for Restricted Stock Units (performance-based) (Filed With SEC on February 26, 2021)
Amendment No. 2 to License and Supply Agreement, dated as of November 5, 2020 by and among Recro Gainesville LLC, Kremers Urban Pharmaceuticals, Inc. and Lannett Company, Inc (Filed With SEC on November 9, 2020)
Description of Securities (Filed With SEC on March 4, 2020)
Manufacturing and Supply Agreement, dated as of February 8, 2019, by and between Recro Pharma, Inc. and Novartis Pharma AG (Filed With SEC on March 6, 2019)
Form of Subordinated Promissory Note (Filed With SEC on August 13, 2021)
Unit Purchase Agreement, dated August 13, 2021, by and among Recro Pharma, Inc., IriSys, LLC, the Sellers (as defined therein), and IriSys, Inc. as the Sellers Representative (Filed With SEC on August 13, 2021)
Form of Non-Qualified Stock Option Inducement Award Agreement (Filed With SEC on August 9, 2021)
Form of Inducement Award Agreement for Restricted Stock Units (Filed With SEC on August 9, 2021)
Underwriting Agreement, dated as of May 12, 2021, by and between Recro Pharma, Inc. and William Blair & Company, L.L.C., as representative of the underwriters (Filed With SEC on May 13, 2021)
Second Amendment to Common Stock Purchase Agreement, by and between Aspire Capital Fund, LLC and Recro Pharma, Inc., dated February 26, 2021 (Filed With SEC on February 26, 2021)
Form of Non-Qualified Stock Option Award Agreement (Filed With SEC on February 26, 2021)
Form of Award Agreement for Restricted Stock Units (Filed With SEC on February 26, 2021)
Fifth Amendment to Credit Agreement and Investment Documents, dated as of February 19, 2021, by and between Recro Pharma, Inc. and Athyrium Opportunities III Acquisition LP (Filed With SEC on February 23, 2021)
Stock Issuance Agreement, dated as of February 19, 2021 by and between Recro Pharma, Inc., Athyrium Opportunities II Acquisition LP and Athyrium Opportunities III Acquisition LP (Filed With SEC on February 23, 2021)
Employment Agreement between Recro Pharma, Inc. and Ryan Lake, dated December 15, 2020 (Filed With SEC on December 21, 2020)
Employment Agreement between Recro Pharma, Inc. and David Enloe, dated December 15, 2020 (Filed With SEC on December 21, 2020)
Fourth Amendment to Credit Agreement and Investment Documents, dated as of November 5, 2020, by and between Recro Pharma, Inc. and Athyrium Opportunities III Acquisition LP (Filed With SEC on November 9, 2020)
First Amendment to Common Stock Purchase Agreement, by and between Aspire Capital Fund, LLC and Recro Pharma, Inc., dated August 7, 2020 (Filed With SEC on August 10, 2020)
Note dated May 12, 2020, between Recro Pharma, Inc. and PNC Bank, National Association (Filed With SEC on May 15, 2020)
Employee Matters Agreement, dated February 12, 2020, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on March 4, 2020)
License and Supply Agreement, dated as of January 1, 2014, by and between Alkermes Pharma Ireland Limited and Kremers Urban Pharmaceuticals, Inc (Filed With SEC on March 4, 2020)
Amendment No. 1 to License and Supply Agreement, dated as of September 6, 2018, by and between Recro Gainesville LLC and Kremers Urban Pharmaceuticals, Inc (Filed With SEC on March 4, 2020)
Partial Assignment, Assumption and Bifurcation Agreement, dated November 20, 2019, by and among Alkermes Pharma Ireland Limited, Recro Gainesville LLC, Recro Pharma, Inc. and... (Filed With SEC on November 26, 2019)
Transition Services Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on November 26, 2019)
Employee Matters Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on November 26, 2019)
Separation Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on November 26, 2019)
Tax Matters Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on November 26, 2019)
Third Amendment to Credit Agreement and Release Agreement, dated as of October 22, 2019, by and between Recro Pharma, Inc. and Athyrium Opportunities III Acquisition LP (Filed With SEC on November 8, 2019)
Separation and Mutual Release Agreement, dated as of May 14, 2019, by and between Recro Pharma, Inc. and Michael Celano (Filed With SEC on May 15, 2019)
Supplemental Agreement No. 3 to the Amended and Restated License and Supply Agreement, dated as of April 15, 2019, by and between Recro Gainesville LLC and Teva Pharmaceutical... (Filed With SEC on April 18, 2019)
Agreement, dated March 25, 2019, by and among Recro Pharma, Inc., Engine Capital, L.P., Engine Jet Capital, L.P., Engine Investments, LLC, and Arnaud Ajdler (Filed With SEC on March 28, 2019)
Second Amendment to Credit Agreement and Investment Documents, dated February 28, 2019, by and among the Recro Pharma, Inc., the guarantors party thereto, the lenders party... (Filed With SEC on March 4, 2019)
Amendment to License Agreement, dated October 31, 2018, by and between Cornell University and Recro Pharma, Inc (Filed With SEC on February 19, 2019)
Common Stock Purchase Agreement, dated February 19, 2019, by and between Recro Pharma, Inc. and Aspire Capital Fund, LLC (Filed With SEC on February 19, 2019)
Registration Rights Agreement, dated February 19, 2019, by and between Recro Pharma, Inc. and Aspire Capital Fund, LLC (Filed With SEC on February 19, 2019)
First Amendment to Credit Agreement and Investment Documents, dated December 28, 2018, by and among the Recro Pharma, Inc., the guarantors party thereto, the lenders party... (Filed With SEC on January 4, 2019)